Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Mais filtros

País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
2.
Curr Opin Infect Dis ; 32(2): 176-186, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30724789

RESUMO

PURPOSE OF REVIEW: We review antivirals inhibiting subunits of the influenza polymerase complex that are advancing in clinical development. RECENT FINDINGS: Favipiravir, pimodivir, and baloxavir are inhibitory in preclinical models for influenza A viruses, including pandemic threat viruses and those resistant to currently approved antivirals, and two (favipiravir and baloxavir) also inhibit influenza B viruses. All are orally administered, although the dosing regimens vary. The polymerase basic protein 1 transcriptase inhibitor favipiravir has shown inconsistent clinical effects in uncomplicated influenza, and is teratogenic effects in multiple species, contraindicating its use in pregnancy. The polymerase basic protein 2 cap-binding inhibitor pimodivir displays antiviral effects alone and in combination with oseltamivir in uncomplicated influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Single doses of the polymerase acidic protein cap-dependent endonuclease inhibitor baloxavir are effective in alleviating symptoms and rapidly inhibiting viral replication in otherwise healthy and higher risk patients with acute influenza, although variants with reduced susceptibility emerge frequently during monotherapy. Combinations of newer polymerase inhibitors with neuraminidase inhibitors show synergy in preclinical models and are currently undergoing clinical testing in hospitalized patients. SUMMARY: These new polymerase inhibitors promise to add to the clinical management options and overall control strategies for influenza virus infections.


Assuntos
Antivirais/administração & dosagem , Desenvolvimento de Medicamentos/tendências , Endorribonucleases/antagonistas & inibidores , Influenza Humana/tratamento farmacológico , Orthomyxoviridae/enzimologia , RNA Polimerase Dependente de RNA/antagonistas & inibidores , Proteínas Virais/antagonistas & inibidores , Antivirais/farmacologia , Ensaios Clínicos como Assunto , Humanos
3.
N Engl J Med ; 372(1): 40-7, 2015 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-25372658

RESUMO

BACKGROUND: In March 2014, the World Health Organization was notified of an outbreak of Zaire ebolavirus in a remote area of Guinea. The outbreak then spread to the capital, Conakry, and to neighboring countries and has subsequently become the largest epidemic of Ebola virus disease (EVD) to date. METHODS: From March 25 to April 26, 2014, we performed a study of all patients with laboratory-confirmed EVD in Conakry. Mortality was the primary outcome. Secondary outcomes included patient characteristics, complications, treatments, and comparisons between survivors and nonsurvivors. RESULTS: Of 80 patients who presented with symptoms, 37 had laboratory-confirmed EVD. Among confirmed cases, the median age was 38 years (interquartile range, 28 to 46), 24 patients (65%) were men, and 14 (38%) were health care workers; among the health care workers, nosocomial transmission was implicated in 12 patients (32%). Patients with confirmed EVD presented to the hospital a median of 5 days (interquartile range, 3 to 7) after the onset of symptoms, most commonly with fever (in 84% of the patients; mean temperature, 38.6°C), fatigue (in 65%), diarrhea (in 62%), and tachycardia (mean heart rate, >93 beats per minute). Of these patients, 28 (76%) were treated with intravenous fluids and 37 (100%) with antibiotics. Sixteen patients (43%) died, with a median time from symptom onset to death of 8 days (interquartile range, 7 to 11). Patients who were 40 years of age or older, as compared with those under the age of 40 years, had a relative risk of death of 3.49 (95% confidence interval, 1.42 to 8.59; P=0.007). CONCLUSIONS: Patients with EVD presented with evidence of dehydration associated with vomiting and severe diarrhea. Despite attempts at volume repletion, antimicrobial therapy, and limited laboratory services, the rate of death was 43%.


Assuntos
Desidratação/etiologia , Doença pelo Vírus Ebola/complicações , Doença pelo Vírus Ebola/mortalidade , Adulto , Fatores Etários , Anti-Infecciosos/uso terapêutico , Diarreia/etiologia , Ebolavirus , Epidemias , Feminino , Febre/etiologia , Hidratação , Guiné/epidemiologia , Doença pelo Vírus Ebola/epidemiologia , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Risco , Taxa de Sobrevida , Taquicardia/etiologia , Vômito/etiologia
4.
Clin Infect Dis ; 63(4): 454-9, 2016 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-27193749

RESUMO

BACKGROUND: Ebola virus disease (EVD) in health workers (HWs) has been a major challenge during the 2014-2015 outbreak. We examined factors associated with Ebola virus exposure and mortality in HWs in Kenema District, Sierra Leone. METHODS: We analyzed data from the Sierra Leone National Viral Hemorrhagic Fever Database, contact tracing records, Kenema Government Hospital (KGH) staff and Ebola Treatment Unit (ETU) rosters, and burial logs. RESULTS: From May 2014 through January 2015, 600 cases of EVD originated in Kenema District, including 92 (15%) HWs, 66 (72%) of whom worked at KGH. Among KGH medical staff and international volunteers, 18 of 62 (29%) who worked in the ETU developed EVD, compared with 48 of 83 (58%) who worked elsewhere in the hospital. Thirteen percent of HWs with EVD reported contact with EVD patients, while 27% reported contact with other infected HWs. The number of HW EVD cases at KGH declined roughly 1 month after implementation of a new triage system at KGH and the opening of a second ETU within the district. The case fatality ratio for HWs and non-HWs with EVD was 69% and 74%, respectively. CONCLUSIONS: The cluster of HW EVD cases in Kenema District is one of the largest ever reported. Most HWs with EVD had potential virus exposure both inside and outside of hospitals. Prevention measures for HWs must address a spectrum of infection risks in both formal and informal care settings as well as in the community.


Assuntos
Surtos de Doenças , Ebolavirus/fisiologia , Doença pelo Vírus Ebola/epidemiologia , Adulto , Feminino , Pessoal de Saúde , Doença pelo Vírus Ebola/etiologia , Doença pelo Vírus Ebola/prevenção & controle , Hospitais , Humanos , Masculino , Pessoa de Meia-Idade , Serra Leoa/epidemiologia
5.
Emerg Infect Dis ; 22(9): 1554-61, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27532807

RESUMO

We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trials of convalescent plasma for passive immunotherapy of MERS-CoV infection may be feasible, but such trials would be challenging because of the small pool of potential donors with sufficiently high antibody titers. Alternative strategies to identify convalescent plasma donors with adequate antibody titers should be explored, including the sampling of serum from patients with more severe disease and sampling at earlier points during illness.


Assuntos
Infecções por Coronavirus/terapia , Infecções por Coronavirus/virologia , Imunoterapia , Coronavírus da Síndrome Respiratória do Oriente Médio/imunologia , Plasma/imunologia , Anticorpos Neutralizantes/imunologia , Anticorpos Antivirais/imunologia , Infecções por Coronavirus/imunologia , Ensaio de Imunoadsorção Enzimática , Pessoal de Saúde , Humanos , Imunoglobulina G/imunologia , Imunoterapia/métodos , Coronavírus da Síndrome Respiratória do Oriente Médio/genética , Testes de Neutralização , RNA Viral , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Arábia Saudita
8.
BMC Anesthesiol ; 16(1): 36, 2016 07 12.
Artigo em Inglês | MEDLINE | ID: mdl-27405596

RESUMO

BACKGROUND: The Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging respiratory pathogen with a high mortality rate and no specific treatments available to date. The purpose of this study was to determine the feasibility of conducting a randomized controlled trial (RCT) of convalescent plasma therapy for MERS-CoV-infected patients by using MERS-CoV-specific convalescent plasma obtained from previously recovered patients. METHODS: A survey was adapted from validated questionnaire originally aimed to measure network capacities and capabilities within the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC). The questionnaire was modified for this study to include 26 items that were divided into three main domains of interest: (1) the ability to care for critically ill MERS-CoV patients; (2) laboratory capacity to diagnose MERS-CoV and blood bank ability to prepare convalescent plasma; and (3), research capacity to conduct randomized controlled trials. The questionnaire was emailed to physicians. RESULTS: Of 582 physicians who were invited to the survey, 327 responded (56.2 %). The professional focus of the majority of respondents was critical care (106/249 (43 %)), pediatrics (59/249, (24 %)) or internal medicine (52/249 (21 %)) but none was blood banking. Nearly all respondents (251/263 (95 %)) reported to have access to ICU facilities within their institutions. Most respondents (219/270 (81 %)) reported that intensivists were the most physician group responsible for treatment decisions about critically ill SARI patients. While 125/165 respondents (76 %) reported that they conduct research in ICUs, and 80/161 (49.7 %) had been involved in the conduct of RCTs, including using a placebo comparison (60/161 (37 %)), only 49/226 (21 %) of respondents regularly participated in research networks. CONCLUSIONS: Our survey indicated that in the Kingdom of Saudi Arabia (KSA), ICUs are the most likely clinical locations for conducting a clinical trial of convalescent plasma therapy for MERS-CoV, and that most ICUs have experience with such research designs.


Assuntos
Atitude do Pessoal de Saúde , Infecções por Coronavirus/sangue , Infecções por Coronavirus/terapia , Médicos/psicologia , Troca Plasmática , Ensaios Clínicos Controlados Aleatórios como Assunto/métodos , Inquéritos e Questionários , Infecções por Coronavirus/virologia , Cuidados Críticos/estatística & dados numéricos , Estudos de Viabilidade , Humanos , Coronavírus da Síndrome Respiratória do Oriente Médio , Arábia Saudita
10.
Am J Respir Crit Care Med ; 190(7): 733-7, 2014 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-25166884

RESUMO

The largest ever Ebola virus disease outbreak is ravaging West Africa. The constellation of little public health infrastructure, low levels of health literacy, limited acute care and infection prevention and control resources, densely populated areas, and a highly transmissible and lethal viral infection have led to thousands of confirmed, probable, or suspected cases thus far. Ebola virus disease is characterized by a febrile severe illness with profound gastrointestinal manifestations and is complicated by intravascular volume depletion, shock, profound electrolyte abnormalities, and organ dysfunction. Despite no proven Ebola virus-specific medical therapies, the potential effect of supportive care is great for a condition with high baseline mortality and one usually occurring in resource-constrained settings. With more personnel, basic monitoring, and supportive treatment, many of the sickest patients with Ebola virus disease do not need to die. Ebola virus disease represents an illness ready for a paradigm shift in care delivery and outcomes, and the profession of critical care medicine can and should be instrumental in helping this happen.


Assuntos
Cuidados Críticos/métodos , Doença pelo Vírus Ebola/terapia , Assistência ao Paciente/métodos , África Ocidental/epidemiologia , Estado Terminal , Surtos de Doenças/estatística & dados numéricos , Doença pelo Vírus Ebola/epidemiologia , Humanos , Cuidados Paliativos/métodos
14.
Influenza Other Respir Viruses ; 12(5): 649-655, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29727522

RESUMO

BACKGROUND: The 2009 influenza A (H1N1) pandemic caused surges of patients in intensive care units (ICUs) in resource-limited settings. Several Ministries of Health requested clinical management guidance from the World Health Organization (WHO), which had not previously developed guidance regarding critically ill patients. OBJECTIVE: To assess the acceptability and impact on knowledge of a short course about the management of critically ill patients with acute respiratory infections complicated by sepsis or acute respiratory distress syndrome delivered to clinicians in resource-limited ICUs. METHODS: Over 4 years (2009-2013), WHO led the development, piloting, implementation and preliminary evaluation of a 3-day course that emphasized patient management based on evidence-based guidelines and used interactive adult-learner teaching methodology. International content experts (n = 35) and instructional designers contributed to development. We assessed participants' satisfaction and content knowledge before and after the course. RESULTS: The course was piloted among clinicians in Trinidad and Tobago (n = 29), Indonesia (n = 38) and Vietnam (n = 86); feedback from these courses contributed to the final version. In 2013, inaugural national courses were delivered in Tajikistan (n = 28), Uzbekistan (n = 39) and Azerbaijan (n = 30). Participants rated the course highly and demonstrated increased immediate content knowledge after (vs before) course completion (P < .001). CONCLUSIONS: We found that it was feasible to create and deliver a focused critical care short course to clinicians in low- and middle-income countries. Collaboration between WHO, clinical experts, instructional designers, Ministries of Health and local clinician-leaders facilitated course delivery. Future work should assess its impact on longer-term knowledge retention and on processes and outcomes of care.


Assuntos
Cuidados Críticos/métodos , Estado Terminal/terapia , Gerenciamento Clínico , Educação Médica/métodos , Competência Profissional/estatística & dados numéricos , Infecções Respiratórias/diagnóstico , Infecções Respiratórias/terapia , Países em Desenvolvimento , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Unidades de Terapia Intensiva , Síndrome do Desconforto Respiratório/diagnóstico , Síndrome do Desconforto Respiratório/terapia , Infecções Respiratórias/complicações , Sepse/diagnóstico , Sepse/terapia
17.
PLoS One ; 10(10): e0140290, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26451847

RESUMO

BACKGROUND: A rapid review, guided by a protocol, was conducted to inform development of the World Health Organization's guideline on personal protective equipment in the context of the ongoing (2013-present) Western African filovirus disease outbreak, with a focus on health care workers directly caring for patients with Ebola or Marburg virus diseases. METHODS: Electronic databases and grey literature sources were searched. Eligibility criteria initially included comparative studies on Ebola and Marburg virus diseases reported in English or French, but criteria were expanded to studies on other viral hemorrhagic fevers and non-comparative designs due to the paucity of studies. After title and abstract screening (two people to exclude), full-text reports of potentially relevant articles were assessed in duplicate. Fifty-seven percent of extraction information was verified. The Grading of Recommendations Assessment, Development and Evaluation framework was used to inform the quality of evidence assessments. RESULTS: Thirty non-comparative studies (8 related to Ebola virus disease) were located, and 27 provided data on viral transmission. Reporting of personal protective equipment components and infection prevention and control protocols was generally poor. CONCLUSIONS: Insufficient evidence exists to draw conclusions regarding the comparative effectiveness of various types of personal protective equipment. Additional research is urgently needed to determine optimal PPE for health care workers caring for patients with filovirus.


Assuntos
Pessoal de Saúde , Doença pelo Vírus Ebola , Doença do Vírus de Marburg , Assistência ao Paciente , Equipamento de Proteção Individual , Animais , Surtos de Doenças , Doença pelo Vírus Ebola/epidemiologia , Doença pelo Vírus Ebola/terapia , Humanos , Doença do Vírus de Marburg/epidemiologia , Doença do Vírus de Marburg/terapia
18.
Springerplus ; 4: 709, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26618098

RESUMO

As of September 30, 2015, a total of 1589 laboratory-confirmed cases of infection with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported to the World Health Organization (WHO). At present there is no effective specific therapy against MERS-CoV. The use of convalescent plasma (CP) has been suggested as a potential therapy based on existing evidence from other viral infections. We aim to study the feasibility of CP therapy as well as its safety and clinical and laboratory effects in critically ill patients with MERS-CoV infection. We will also examine the pharmacokinetics of the MERS-CoV antibody response and viral load over the course of MERS-CoV infection. This study will inform a future randomized controlled trial that will examine the efficacy of CP therapy for MERS-CoV infection. In the CP collection phase, potential donors will be tested by the enzyme linked immunosorbent assay (ELISA) and the indirect fluorescent antibody (IFA) techniques for the presence of anti-MERS-CoV antibodies. Subjects with anti-MERS-CoV IFA titer of ≥1:160 and no clinical or laboratory evidence of MERS-CoV infection will be screened for eligibility for plasma donation according to standard donation criteria. In the CP therapy phase, 20 consecutive critically ill patients admitted to intensive care unit with laboratory-confirmed MERS-CoV infection will be enrolled and each will receive 2 units of CP. Post enrollment, patients will be followed for clinical and laboratory outcomes that include anti-MERS-CoV antibodies and viral load. This protocol was developed collaboratively by King Abdullah International Medical Research Center (KAIMRC), Gulf Cooperation Council (GCC) Infection Control Center Group and the World Health Organization-International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC-WHO) MERS-CoV Working Group. It was approved in June 2014 by the Ministry of the National Guard Health Affairs Institutional Review Board (IRB). A data safety monitoring board (DSMB) was formulated. The study is registered at http://www.clinicaltrials.gov (NCT02190799).

19.
Jpn J Infect Dis ; 56(2): 43-7, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12824683

RESUMO

The purpose of our study was to establish a seasonal model to simulate the oscillation of the number of influenza cases with weather conditions and calendar months in Tokyo, Japan, during the winter season. Surveillance data for influenza in Tokyo was retrieved from the Infectious Agents Surveillance Report, published by the National Institute of Infectious Diseases in Japan. We obtained data for 86 parameters of weather conditions from the Meteorological Agency. The best-fit model was built by multiple regression with stepwise analysis. The reported number of patients with influenza per week was significantly increased with fewer days of maximum temperature 10 per week (T10) and more days of relative humidity <60% per week (S60), adjusted by calendar month, average temperature, and vapor pressure. Annual oscillation of the number of reported influenza cases at the start, peak, and end weeks almost exactly matched the model, although peak levels for each oscillation did not always match. However, this model showed that 81% of the variation among the observed number of influenza cases was explained by a linear relationship with the seasonal parameters utilized. The validity of this model applied to data from 1999 to 2002, showing a 75% correlation. Using this model, if the number of days with both T10 and S60 increased by one per week, the number of influenza cases was simulated to decrease by approximately half. These results suggest that most of the oscillation in the number of influenza cases may be explained using a seasonal model that can simulate the impact of global warming.


Assuntos
Influenza Humana/epidemiologia , Modelos Biológicos , Estações do Ano , Humanos , Incidência , Reprodutibilidade dos Testes , Tóquio/epidemiologia , Tempo (Meteorologia)
20.
Jpn J Infect Dis ; 56(2): 48-53, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12824684

RESUMO

In order to investigate the effects of global warming, we attempted to establish seasonal models to predict fluctuations in rates of herpangina (HA) and hand-foot-mouth disease (HFMD) associated with weather conditions and calendar months in Tokyo, Japan. Surveillance data tracking HA/HFMD incidences in Tokyo was retrieved from the Infectious Agents Surveillance Report, published by the National Institute of Infectious Diseases in Japan. From the Meteorological Agency, we obtained data for 54 weather condition parameters. The annual fluctuations in reported HA cases comprising start, peak, and end weeks almost exactly matched the model, although peak levels for each fluctuation did not always match in HFMD. Furthermore, for the HA model, 88% of the variations among observed HA cases were explained by the linear relationship with the seasonal parameters investigated, which was higher than the 64% observed for the HFMD model. The HA and HFMD models were applied to data from the years 1999 to 2002, and demonstrated correlations of 86% and 64%, respectively. These models predicted that warmer climate conditions would lead to an increased number of HA and HFMD cases. These results suggest that our seasonal models may quantify the dependency of infectious diseases on seasonal parameters and simulate the impact of global warming.


Assuntos
Doença de Mão, Pé e Boca/epidemiologia , Herpangina/epidemiologia , Estações do Ano , Tempo (Meteorologia) , Criança , Humanos , Modelos Biológicos , Temperatura , Tóquio/epidemiologia , Urbanização
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA